drugset / Trial / NCT01942668

A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms

NCT01942668

Phase 3 Completed 1845 enrolled TherapeuticsMD
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will be a prospective, randomized, double-blind, placebo-controlled, parallel group, multicenter trial of postmenopausal subjects with an intact uterus.

Timeline

Start
2013-08-05
Primary completion
2016-10-28
Completion
2016-10-28

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Estradiol Other / unclassified 0.25 mg Oral
Subject Estradiol Other / unclassified 0.5 mg Oral
Subject Estradiol Other / unclassified 1 mg Oral
Subject Progesterone Other / unclassified 50 mg Oral
Subject Progesterone Other / unclassified 100 mg Oral

Indications

No indication recorded.